Option Care Health (NASDAQ:OPCH) Updates FY 2025 Earnings Guidance

Option Care Health (NASDAQ:OPCH - Get Free Report) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of 1.590-1.690 for the period, compared to the consensus estimate of 1.240. The company issued revenue guidance of $5.2 billion-$5.4 billion, compared to the consensus revenue estimate of $5.2 billion. Option Care Health also updated its FY 2024 guidance to 1.550-1.590 EPS.

Option Care Health Stock Up 15.5 %

Option Care Health stock traded up $3.73 during mid-day trading on Monday, reaching $27.72. 5,927,819 shares of the company's stock were exchanged, compared to its average volume of 2,115,454. The company has a fifty day moving average of $23.20 and a 200-day moving average of $27.69. The company has a market cap of $4.72 billion, a P/E ratio of 23.29, a P/E/G ratio of 2.43 and a beta of 1.31. The company has a quick ratio of 1.32, a current ratio of 1.73 and a debt-to-equity ratio of 0.77. Option Care Health has a twelve month low of $21.39 and a twelve month high of $34.63.

Wall Street Analyst Weigh In

A number of brokerages recently commented on OPCH. Bank of America upgraded shares of Option Care Health from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $26.00 to $33.00 in a research note on Monday. Barrington Research lowered their price target on Option Care Health from $40.00 to $32.00 and set an "outperform" rating for the company in a report on Thursday, October 31st. UBS Group began coverage on shares of Option Care Health in a research report on Thursday, December 5th. They set a "neutral" rating and a $26.00 price objective for the company. JMP Securities reaffirmed a "market outperform" rating and set a $30.00 price target (down previously from $31.00) on shares of Option Care Health in a research report on Friday. Finally, Truist Financial decreased their price objective on Option Care Health from $41.00 to $34.00 and set a "buy" rating for the company in a research report on Friday, November 1st. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $29.71.

Insiders Place Their Bets

In related news, Director Harry M. Jansen Kraemer, Jr. purchased 43,000 shares of the stock in a transaction that occurred on Friday, November 8th. The stock was purchased at an average cost of $22.54 per share, for a total transaction of $969,220.00. Following the acquisition, the director now owns 326,334 shares in the company, valued at approximately $7,355,568.36. This trade represents a 15.18 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.64% of the stock is owned by corporate insiders.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.